Patents Assigned to JS INNOPHARM (SHANGHAI) LTD.
  • Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof
    Patent number: 11548868
    Abstract: Disclosed herein are compounds of formula I and/or a stereoisomer, stable isotopologue, and/or pharmaceutically acceptable salts thereof; and therapeutic uses of these compounds, which are inhibitors of tryptophan 2, 3-dioxygenase 2 (TDO2) and/or indoleamine 2, 3-dioxygenase 1 (IDO1), potentially useful in the treatment of diseases treatable, such as cancers.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: January 10, 2023
    Assignee: JS Innopharm (Shanghai) Ltd.
    Inventors: Jintao Zhang, Wen Xu, Shanzhong Jian, Ao Li, Qun Li
  • Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
    Patent number: 11242334
    Abstract: (I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and therapeutic uses of these compounds, which are kinase inhibitors potentially useful in the treatment of diseases treatable, such as cancers, as well as pharmaceutical compositions, comprising a compound of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: February 8, 2022
    Assignee: JS Innopharm (Shanghai) Ltd.
    Inventors: Jintao Zhang, Wen Xu, Shanzhong Jian, Qun Li
  • Heterocyclic compounds as ERK inhibitors
    Patent number: 10479791
    Abstract: Disclosed herein is a compound of formula I and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors: They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: November 19, 2019
    Assignees: CHANGZHOU JIEKAI PHARMATECH CO. LTD, JS INNOPHARM (SHANGHAI) LTD
    Inventors: Jintao Zhang, Wen Xu, Shanzhong Jian
  • HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS
    Publication number: 20180179211
    Abstract: Disclosed herein is a compound of formula I and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors: They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 3, 2015
    Publication date: June 28, 2018
    Applicants: CHANGZHOU JIEKAI PHARMATECH CO. LTD, JS INNOPHARM (SHANGHAI) LTD
    Inventors: Jintao ZHANG, Wen XU, Shanzhong JIAN
  • HETEROCYCLIC COMPOUNDS FOR TREATING PSORIASIS
    Publication number: 20180169096
    Abstract: Disclosed herein is a method of treating psoriasis involving the use of compound of formula I and/or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: June 3, 2015
    Publication date: June 21, 2018
    Applicant: JS INNOPHARM (SHANGHAI) LTD.
    Inventors: Jintao ZHANG, Quanhai LIU, Minyu LIU, Xiaoling HUANG, Yifang DENG, Pengxia YU